A new platform, named Virtual Synthon Hierarchical Enumeration Screening, has been developed by researchers to efficiently discover drugs.
List view / Grid view
Dr Antal Szalay, CEO and Founder of Ultimate Medicine, explores how the analysis of omics data, especially metabolomics and proteomics, can provide researchers with vital insight that can inform the development of drugs for conditions associated with age.
GlaxoSmithKline (GSK) and the University of Oxford will collaborate to investigate diseases using technologies such as functional genomics and machine learning.
An experimental drug for liver cancer and Dasatinib, approved for chronic myeloid leukaemia could be repurposed to treat Alzheimer's disease.
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
First-of-its-kind study uses a multi-omics approach to provide a list of causal candidate genes associated with alcohol use disorder (AUD).
UK researchers have created a metal-based molecule that inhibits the build-up of Alzheimer’s-associated peptide, amyloid-β, in lab tests.
US researchers have identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that could be used against these targets.
In brain tissues, researchers have shown that two different nanosized polyoxoniobate molecules can inhibit the assembly of amyloid plaques.
A new gene therapy that introduced SynCav1 to the brains of Alzheimer's mouse models was shown to preserve neuronal and synaptic plasticity.
A novel sensitive label-free imaging method has been developed to visualise brain samples using an FxClear-based tissue clearing technique.
Researchers have shown that Chroman 1, Emricasan and trans-ISRIB, in combination with polyamines, are effective at protecting induced pluripotent stem cells from stress.
Oral doses of a new drug named CA administered to mouse models led to improvements in Alzheimer's disease, including memory.